{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:35:05Z","timestamp":1788586505359,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T00:00:00Z","timestamp":1692921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jacadv.2023.100622","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T18:30:31Z","timestamp":1695666631000},"page":"100622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Medical Therapies to Improve Left\u00a0Ventricular Outflow Obstruction and\u00a0Diastolic Function in Hypertrophic\u00a0Cardiomyopathy"],"prefix":"10.1016","volume":"2","author":[{"given":"Mason","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klevin Roger L.","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Bilgili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lee Claggett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1045-2698","authenticated-orcid":false,"given":"Timothy C.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari S.","family":"Naidu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Willeford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-5096","authenticated-orcid":false,"given":"Florian","family":"Rader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jacadv.2023.100622_bib1","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/1873-3468.13496","article-title":"Energetic drain driving hypertrophic cardiomyopathy","volume":"593","author":"Sequeira","year":"2019","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100622_bib2","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1161\/01.CIR.91.12.2911","article-title":"A\u00a0myosin missense mutation, not a null allele, causes familial hypertrophic cardiomyopathy","volume":"91","author":"Nishi","year":"1995","journal-title":"Circulation"},{"issue":"Suppl 2","key":"10.1016\/j.jacadv.2023.100622_bib3","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.21037\/cdt.2019.02.01","article-title":"Hypertrophic cardiomyopathy: genetics and clinical perspectives","volume":"9","author":"Wolf","year":"2019","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.jacadv.2023.100622_bib4","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24634","article-title":"Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes","volume":"6","author":"Alamo","year":"2017","journal-title":"Elife"},{"issue":"35","key":"10.1016\/j.jacadv.2023.100622_bib5","doi-asserted-by":"crossref","first-page":"E8143","DOI":"10.1073\/pnas.1809540115","article-title":"Deciphering the super relaxed state of human beta-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers","volume":"115","author":"Anderson","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12551-017-0274-6","article-title":"Hypertrophic cardiomyopathy and the myosin mesa: viewing an old disease in a new light","volume":"10","author":"Trivedi","year":"2018","journal-title":"Biophys Rev"},{"issue":"10","key":"10.1016\/j.jacadv.2023.100622_bib7","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/cvr\/cvy147","article-title":"Metabolic changes in hypertrophic cardiomyopathies: scientific update from the working group of myocardial function of the European Society of Cardiology","volume":"114","author":"van der Velden","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/01.RES.83.6.580","article-title":"Familial hypertrophic cardiomyopathy: from mutations to functional defects","volume":"83","author":"Bonne","year":"1998","journal-title":"Circ Res"},{"issue":"10","key":"10.1016\/j.jacadv.2023.100622_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.121.056324","article-title":"Myosin modulation in hypertrophic cardiomyopathy and systolic heart failure: getting inside\u00a0the engine","volume":"144","author":"Daniels","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacadv.2023.100622_bib10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100622_bib11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00424-019-02259-2","article-title":"Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations","volume":"471","author":"Spudich","year":"2019","journal-title":"Pflugers Arch"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100622_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40256-022-00532-x","article-title":"The Impact of mavacamten on the Pathophysiology of hypertrophic cardiomyopathy: a narrative review","volume":"22","author":"Edelberg","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/ars.2017.7236","article-title":"Hypertrophic cardiomyopathy: a vicious cycle triggered by sarcomere mutations and secondary disease hits","volume":"31","author":"Wijnker","year":"2019","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.tips.2011.02.010","article-title":"Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling","volume":"32","author":"Baker","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/0002-9343(78)90700-3","article-title":"Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure","volume":"65","author":"Mason","year":"1978","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100622_bib16","first-page":"260","article-title":"Left ventricular outflow tract obstruction in ICU patients","volume":"22","author":"Slama","year":"2016","journal-title":"Curr Opin Crit Care"},{"issue":"25","key":"10.1016\/j.jacadv.2023.100622_bib17","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100622_bib18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.amjcard.2012.04.051","article-title":"Beta blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy","volume":"110","author":"Nistri","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2023.100622_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2022.03.013","article-title":"Bisoprolol for treatment of symptomatic patients with obstructive hypertrophic cardiomyopathy. The BASIC (bisoprolol AS therapy in hypertrophic cardiomyopathy) study","volume":"354","author":"Monda","year":"2022","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium channel blockers: an update","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1161\/01.CIR.60.6.1208","article-title":"Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status","volume":"60","author":"Rosing","year":"1979","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100622_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/hrt.51.5.523","article-title":"Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function","volume":"51","author":"Anderson","year":"1984","journal-title":"Br Heart J"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100622_bib23","doi-asserted-by":"crossref","first-page":"185B","DOI":"10.1016\/0002-9149(85)90630-7","article-title":"Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy","volume":"55","author":"Rosing","year":"1985","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0002-9149(96)00336-0","article-title":"Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy","volume":"78","author":"Betocchi","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2023.100622_bib25","series-title":"StatPearls","article-title":"Disopyramide","author":"Sundjaja","year":"2023"},{"issue":"16","key":"10.1016\/j.jacadv.2023.100622_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJM198210143071607","article-title":"Muscular subaortic stenosis: hemodynamic and clinical improvement after disopyramide","volume":"307","author":"Pollick","year":"1982","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.jacadv.2023.100622_bib27","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/0002-9149(88)90268-8","article-title":"Disopyramide in hypertrophic cardiomyopathy. I. Hemodynamic assessment after intravenous administration","volume":"62","author":"Pollick","year":"1988","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib28","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/0002-8703(93)90760-7","article-title":"Acute dose-response effects of intravenous disopyramide in hypertrophic obstructive cardiomyopathy","volume":"125","author":"Kimball","year":"1993","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.jacadv.2023.100622_bib29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0002-9149(88)90553-X","article-title":"Oral disopyramide therapy for obstructive hypertrophic cardiomyopathy","volume":"62","author":"Sherrid","year":"1988","journal-title":"Am J Cardiol"},{"issue":"8","key":"10.1016\/j.jacadv.2023.100622_bib30","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2023.100622_bib31","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2010.06.059","article-title":"Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline","volume":"106","author":"Kajimoto","year":"2010","journal-title":"Am J Cardiol"},{"issue":"11","key":"10.1016\/j.jacadv.2023.100622_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"issue":"10253","key":"10.1016\/j.jacadv.2023.100622_bib34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jacadv.2023.100622_bib36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy Referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib38","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib39","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.echo.2007.11.006","article-title":"Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns: an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy","volume":"21","author":"Menon","year":"2008","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"11","key":"10.1016\/j.jacadv.2023.100622_bib40","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/hrt.35.11.1116","article-title":"Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy","volume":"35","author":"Hubner","year":"1973","journal-title":"Br Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/oxfordjournals.eurheartj.a061160","article-title":"Reappraisal of the effect of acute betablockade on left ventricular filling dynamics in hypertrophic obstructive cardiomyopathy","volume":"2","author":"Speiser","year":"1981","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02524797","article-title":"Effects of low-dose dobutamine on left ventricular diastolic filling in children","volume":"17","author":"Harada","year":"1996","journal-title":"Pediatr Cardiol"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100622_bib43","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF00880155","article-title":"Effect of dobutamine on left ventricular relaxation and filling phase in patients with ischemic heart disease and preserved systolic function","volume":"7","author":"Zeppellini","year":"1993","journal-title":"Cardiovasc Drugs Ther"},{"issue":"16","key":"10.1016\/j.jacadv.2023.100622_bib44","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jacc.2022.02.024","article-title":"Effects of metoprolol on exercise hemodynamics in patients with obstructive hypertrophic cardiomyopathy","volume":"79","author":"Dybro","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"21","key":"10.1016\/j.jacadv.2023.100622_bib45","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.jacc.2021.08.073","article-title":"Effect of beta-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction","volume":"78","author":"Palau","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2023.100622_bib46","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijcard.2010.08.026","article-title":"Chronotropic incompetence and its relation to exercise intolerance in hypertrophic cardiomyopathy","volume":"153","author":"Efthimiadis","year":"2011","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib47","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/0002-9149(80)90487-7","article-title":"Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy","volume":"45","author":"Hanrath","year":"1980","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib48","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1378\/chest.84.1.54","article-title":"Left ventricular end-diastolic pressure-volume relationships in hypertrophic cardiomyopathy. Changes induced by verapamil","volume":"84","author":"Tendera","year":"1983","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib49","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1161\/01.CIR.68.6.1274","article-title":"Effects of short-term administration of verapamil on left ventricular relaxation and filling dynamics measured by a combined hemodynamic-ultrasonic technique in patients with hypertrophic cardiomyopathy","volume":"68","author":"TenCate","year":"1983","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib50","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"issue":"Suppl F","key":"10.1016\/j.jacadv.2023.100622_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/eurheartj\/4.suppl_F.47","article-title":"Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness","volume":"4","author":"Hess","year":"1983","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.jacadv.2023.100622_bib52","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0002-9149(84)80142-3","article-title":"Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: an echocardiographic study","volume":"54","author":"Suwa","year":"1984","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2023.100622_bib53","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/clc.4960100106","article-title":"Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy","volume":"10","author":"Doiuchi","year":"1987","journal-title":"Clin Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100622_bib54","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/phar.1664","article-title":"Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug","volume":"35","author":"Verlinden","year":"2015","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.jacadv.2023.100622_bib55","first-page":"795","article-title":"Electrophysiological and contractile effects of disopyramide in patients with obstructive hypertrophic cardiomyopathy: a translational study","volume":"4","author":"Coppini","year":"2019","journal-title":"J Am Coll Cardiol Basic Trans Science"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib56","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/BF00054192","article-title":"Effect of disopyramide on left ventricular diastolic function in patients with hypertrophic cardiomyopathy: comparison with diltiazem","volume":"6","author":"Sumimoto","year":"1992","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.jacadv.2023.100622_bib57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0735-1097(95)00229-W","article-title":"Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy","volume":"26","author":"Matsubara","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacadv.2023.100622_bib58","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0002-9149(94)90416-2","article-title":"Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy","volume":"74","author":"Fifer","year":"1994","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2023.100622_bib59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2023.100622_bib60","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1161\/CIRCULATIONAHA.122.062534","article-title":"Dose-blinded myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: Outcomes through 32 weeks","volume":"147","author":"Desai","year":"2023","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.jacadv.2023.100622_bib61","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with Nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.jacadv.2023.100622_bib62","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic Features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2023.100622_bib63","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten Favorably Impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance Substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2023.100622_bib64","doi-asserted-by":"crossref","first-page":"e014986","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin\u00a0inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X23005938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X23005938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:58:06Z","timestamp":1757426286000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X23005938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2772963X23005938"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2023.100622","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies to Improve Left\u00a0Ventricular Outflow Obstruction and\u00a0Diastolic Function in Hypertrophic\u00a0Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2023.100622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"100622"}}